Thus, while there are some conflicting reports, the majority of studies on sPD-1 suggest that levels are elevated in cancer patients compared to healthy donors, and that higher levels are most typically associated with a more advanced cancer phenotype. This evidence concerns the gene HOXD13 and cancer.